Jagpreet Grewal
@jgrewal_12
Sikh | Advanced Heart Failure and Transplant Cardiologist
ID: 53699791
04-07-2009 16:09:21
100 Tweet
239 Followers
569 Following
Witnessed out of hospital cardiac arrest. EF 10% by #POCUS, hypoxic on FiO2 100. V-A ECMO with antegrade distal perfusion and #ImpellaCP placed at bedside WITHOUT Fluoro using only #echofirst guidance for placement. Our team is strong and ready for the #waronshock مستشفى الوادي الطبي valley medical hospital
A simple ‘mini’ invasive hemodynamic test to diagnose HFpEF Circ: Heart Failure Wedge pressure ≥19 mmHg with passive leg raising (no exercise) had a 100% specificity for the diagnosis of HFpEF #cardiotwitter #MedEd ahajournals.org/doi/abs/10.116…
Hot off the press! Long term results of TICTAC trial comparing TAC monotherapy to TAC and MMF from AHFTC fellow at MUSC Jagpreet Grewal and David Baran! Importance of individualizing immunosuppression to avoid over-/under-treatment post-transplant. MUSC Cardiology MUSC Cardiology Fellowship Programs
This is an underutilized slide Javed Butler - it should be emphasized HF talks. Would like to underscore the misnomer of “stable” HF patients when referring to those that are compensated. Because look at that event rate! (EXTREMELY HIGH RISK) Steve Greene Gregg Fonarow MD
Cardiovascular Research Foundation Karl-Philipp Rommel Brian Whisenant Anju Bhardwaj MD FACC Javed Butler @KashviGupta Alexander Hajduczok, MD 🇺🇦🙏 @DrNasrien Anu Lala-Trindade Henry Han Andrew J Sauer MD Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA Check out this one by star AHFTC MUSC Cardiology Fellowship Programs Jagpreet Grewal. Does duration of cf-LVAD support influence post-transplant outcomes? You might find the answer surprising! Michael Rofael @Brian_Houston12 Abbott Robert Kormos Jennifer Hajj, RN Jan Griffin Arman Kilic
Nice presentation The ISHLT by MUSC Cardiology AHFTC fellow Jagpreet Grewal - presenting a multi center real world analysis of the HM3 risk score and outcomes! Manreet Kanwar Farooq Sheikh @Brian_Houston12 Matt Lander Palak Shah Steven Hsu @mikegenuardi Jennifer Hajj, RN @IRajapreyar
Big news indeed! “The outstanding results of the ATTRibute-CM study provide new hope to patients living with transthyretin amyloid cardiomyopathy, or ATTR-CM”, said Dr. Daniel Judge, Professor of Medicine/Cardiology MUSC Health & Co-Chair of the ATTRibute-CM Steering Committee"
Does Duration of Durable cf-LVAD Support Impact Heart Transplant Outcomes? Our UNOS analysis led by last year's MUSC Cardiology AHFTC fellow Jagpreet Grewal in JACC Journals suggests it doesn't! Jennifer Hajj, RN Lucas Witer Jan Griffin @Brian_Houston12 #THT sciencedirect.com/science/articl…
How do you risk stratify candidates for LVADs? Former MUSC Health AHFTC fellow Jagpreet Grewal led this Multi-Center Evaluation of the HeartMate 3 Risk Score JHLT jhltonline.org/article/S1053-… While HM3RS was less predictive in non-trial populations, outcomes were still excellent.
This is a really nice study by Jagpreet Grewal Ryan J Tedford MD and others! Real-world risk stratification of HM3 candidates! Great outcomes but additional opportunities to optimally evaluate real-world, non-trial patients!
In a multi-center cohort, the HM3 risk score provided adequate risk discrimination in “trial-like” pts but was less predictive in pts who did not meet trial criteria Ryan J Tedford MD @MRMehraMD Farooq Sheikh Jagpreet Grewal Alexander Hajduczok, MD 🇺🇦🙏 🔗 jhltonline.org/article/S1053-…
Dr. Grewal presented an excellent overview of PH for RWJ cardiology grand rounds today. Challenges remain for cPC-PH. Opportunities for treatment options! Option for sotatercept? Partho P Sengupta Jagpreet Grewal
Representing Robert Wood Johnson UH at THT #THT2025 Rutgers RWJMS Cardiology Fellowship Partho P Sengupta Maya Guglin Jagpreet Grewal excellent meeting with great discussions and novel interventions for heart failure.
